CholesterolConflicts of InterestHeart DiseaseMedicationsNewsletter

Surrogate end points are bad for your health

If I told you that a drug went on sale on 1st September 2015, which involved fortnightly injections at a cost of £4,000 a year and for which trials on incidents or deaths had not even started, you might be shocked. That’s exactly what happened last week. A drug named “Repatha” went on sale, having been “granted marketing authorisation” (not approval?!) by the European Medicines agency on 21st May 2015.


The rest of this article is available to site subscribers, who get access to all articles plus a weekly newsletter.
To continue reading, please login below or sign up for a subscription. Thank you.